ArriVent BioPharma, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Research and development | $153.4M | $79.0M | $64.9M | — |
| Operating expenses | $177.5M | $94.3M | $74.6M | — |
| Operating income | -$177.5M | -$94.3M | -$74.6M | — |
| Net income | -$166.3M | -$80.5M | -$69.3M | — |
| Balance Sheet | ||||
| Cash and equivalents | $45.5M | $74.3M | $150.4M | — |
| Current assets | $332.9M | $227.0M | $160.0M | — |
| Total assets | $333.2M | $274.9M | $163.1M | — |
| Current liabilities | $25.9M | $17.3M | $11.6M | — |
| Total liabilities | $25.9M | $17.3M | $11.8M | — |
| Stockholders' equity | $307.2M | $257.7M | -$153.2M | -$85.1M |
| Cash Flow Statement | ||||
| Cash from operations | -$160.6M | -$70.2M | -$55.8M | — |
| Depreciation and amortization | $3.0M | — | — | — |
| Stock-based compensation | $12.5M | $3.2M | $895,000 | — |
Shares outstanding 46.6M · Free float 68.2%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.